Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex...

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Previous stent trials excluded complex lesions and did not evaluate platelet inhibition.
• This analysis focuses on the impact of stenting and abciximab in complex coronary lesions.

Purpose of the Study:

• To assess the combined effect of stenting and abciximab in patients with complex coronary lesions.
• To evaluate long-term outcomes including death, myocardial infarction, and target vessel revascularization.

Main Methods:

• Analysis of patients with complex lesions from the EPILOG and EPISTENT trials.
• Comparison of four treatment groups: balloon angioplasty/placebo, stent/placebo, balloon angioplasty/abciximab, and stent/abciximab.
• Multivariate analysis to adjust for baseline differences and identify independent predictors of outcomes.

Main Results:

• The combination of stenting and abciximab significantly reduced the combined rate of death or myocardial infarction (8.0%) compared to other groups (P<0.001).
• Death rates were significantly lower in the stent/abciximab group (0.5%) compared to balloon angioplasty/placebo (3.2%) (P=0.03).
• Target vessel revascularization was reduced by both stenting and abciximab, with the stent/abciximab group showing a significant reduction (19.7%) compared to balloon angioplasty/placebo (30.5%) (P<0.001).

Conclusions:

• The combination of stenting and abciximab provides additive long-term benefits for patients with complex coronary lesions.
• This therapeutic strategy significantly reduces the risk of death, myocardial infarction, and target vessel revascularization.
• The findings support the use of combined stenting and abciximab in percutaneous coronary interventions for complex lesions.